Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
ADC, adjourn, Adjournment, Amgen, attached, attend, auristatin, Bicycle, black, blockade, box, bridge, Canada, card, chain, Charter, chemistry, combo, companion, conjugate, conjugation, consumption, CSPC, defeat, diagnostic, dismissed, diversify, Eastern, eighteen, Eli, Enfortumab, enzyme, exact, Fc, freight, geopolitical, headquartered, hearing, immunoregulation, impeded, incretin, inflationary, inhibitor, intergovernmental, invasion, jointly, labor, leptinemia, Lilly, linker, liraglutide, Mabwell, macroeconomic, mandatorily, maximum, Megalith, mezzanine, military, MMAE, monomethyl, MounjaroTM, movement, neuropathy, Nordisk, Novo, outpace, PADCEV, payload, play, prejudice, PRI, reclassified, reclassify, redeemable, redeemed, redemption, regional, retaliatory, Russian, SaxendaTM, Seagen, Secretary, split, subset, TCJA, Ukraine, understood, undertaken, untapped, urothelial, vedotin, WegovyTM
Removed:
activated, add, arisen, autoimmune, baseline, blood, bone, Budget, cardiac, CDASI, closure, collagen, communicable, consummated, deferring, DM, enrolled, external, feedback, focused, forcing, geography, globally, GMP, heightened, impacted, importance, ineffective, inhibition, involvement, lipid, lung, muscle, NIH, nonclinical, observed, pathogenic, preclinical, preferentially, preliminary, preventing, regulated, renal, ship, showed, sixteen, SLE, spread, stipulated, stop, strain, supported, surfaced, syndrome, taxing, topline, transmissible, travel, underwritten, widespread, withdraw, worsening, Wuhan
Filing tables
Filing exhibits
Related press release
CRBP similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the Registration Statements of Corbus Pharmaceuticals Holdings, Inc. on Form S-3 (No. 333-237588) and Form S-8 (Nos. 333-200350, 333-201898, 333-210428, 333-216547, 333-223745, 333-230219, 333-237240, and 333-254350) of our report dated March 7, 2023, on our audits of the financial statements as of December 31, 2022 and 2021 and for each of the years then ended, which report is included in this Annual Report on Form 10-K to be filed on or about March 7, 2023.
/s/ EisnerAmper LLP
EISNERAMPER LLP
Philadelphia, Pennsylvania
March 7, 2023